Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%.

Stellantis and Factorial Energy have validated a semi-solid state battery cell. The milestone brings the tech one step closer to commercialization. Factorial's cells bring significant advantages in ...

Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...

Before biopharmaceutical companies raise money from venture capital firms, their early funding often comes from the U.S. government in the form National Institutes of Health grants. That was the case ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Factorial is making swift progress on its all-solid-state EV batteries, which were introduced with Mercedes-Benz just a few months ago. Its first all-solid-state EV battery cells, promising to boost ...

The last time I wrote about Recursion Pharmaceuticals, Inc. (RXRX), it was in a Seeking Alpha article entitled “Recursion: Path Forward For REC-994 Remains Despite Mixed Response.” In the article, I ...